Compare Duolingo Inc (DUOL) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duolingo Inc vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Duolingo Inc trades at $150.02 (market cap $7.08B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.88 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 3.6× Duolingo Inc's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duolingo Inc for 137 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| DUOL | RPRX | |
|---|---|---|
Market Cap | $7.08B | $25.27B |
Volume | 729,171 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $341.08 | $63.96 |
52-Week Low | $90.03 | $35.44 |
Typical Hold Time | 137 Days | 1 Days |
Enterprise Value | $5.85B | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duolingo (DUOL) trades at $149.92, down 1.19% on the day, as the stock consolidates near key technical support levels. The company demonstrates strong fundamental momentum with Q2 2026 EPS beating expectations at $0.66 versus $0.60, continuing a pattern of earnings outperformance. Revenue growth remains robust at 39% year-over-year for 2025, reaching $1.04 billion, while maintaining exceptional profitability with a 35.87% net income margin. Technical indicators show a bullish moving average configuration despite neutral oscillators.
Duolingo presents a compelling growth story with accelerating revenue expansion and industry-leading margins, though valuation multiples appear elevated with a P/E of 17.87 and P/S of 6.47. Key risks include CEO share sales totaling $4.3 million in September 2026 and competitive pressures in the edtech space. Analyst consensus leans cautious with 54% hold ratings, suggesting the stock may be fairly valued near current levels despite strong operational performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duolingo Inc
Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
